"SJN314 and ADC Platform Highly Valued"

Samjin Pharmaceutical announced on the 6th that it has been finally selected as a supported company for the "2026 World Class Plus Project," led and managed by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology (KIAT).


The "World Class Plus Project" is a government program that selects promising mid-sized companies with global growth potential and competitiveness, then provides a package of support including research and development (R&D), export assistance, financial support, and consulting. Samjin Pharmaceutical will receive government support for R&D funding for up to four years going forward.


Samjin Pharmaceutical has been finally selected as a supported company for the '2026 World Class Plus Project,' which is organized and managed by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology (KIAT). Samjin Pharmaceutical

Samjin Pharmaceutical has been finally selected as a supported company for the '2026 World Class Plus Project,' which is organized and managed by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology (KIAT). Samjin Pharmaceutical

View original image

Back in April, Samjin Pharmaceutical was named as a representative company in the advanced bio sector among ten mid-sized companies that passed rigorous screening in cutting-edge national industries such as bio, semiconductors, and future mobility in Korea.


During the selection process for this project, the company earned high scores for the technical complexity and commercialization potential of its tasks: "Innovative New Drug Advancement" and "Development of Technologies Based on Formulation and Antibody-Drug Conjugate (ADC) Platforms." In particular, Samjin Pharmaceutical explained that its core pipeline—including SJN314, an immunology/inflammation therapy, and its ADC platform—were recognized as innovative technologies with strong potential for commercialization and early revenue generation, as well as a solid foundation for entering global markets.


Samjin Pharmaceutical has been consistently investing about 12% of its sales in research and development. Looking ahead, the company aims to further strengthen its revenue model through expanded technology exports and step-by-step technology transfers based on its collaborative network with global pharmaceutical companies. In addition, the company plans to accelerate its entry into the global market by leveraging its overseas business networks so that technology exports seamlessly lead through to commercialization.



Samjin Pharmaceutical's Executive Vice President in charge of R&D, Soo Min Lee, said, "Going forward, we will do our utmost to realize tangible results in global technology exports centered on our core pipeline and platform technologies, and to accelerate the strengthening of our competitiveness in the global market so that Samjin Pharmaceutical firmly establishes itself as a 'global anchor company.'"


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing